Article Text

Download PDFPDF
Post-COVID mRNA vaccine myocarditis in children: report of two cases
  1. Ahmed Shamekh1,
  2. Colin Powell2,
  3. Abdusamea Ashabani1 and
  4. Ibtihal Siddiq Abdelgadir3
  1. 1Paediatric Emergency, Sidra Medicine, Doha, Ad Dawhah, Qatar
  2. 2Paediatrics, Cardiff and Vale University Health Board, Cardiff, UK
  3. 3Paediatric Emergency, Sidra Medical and Research Center, Doha, Qatar
  1. Correspondence to Dr Ahmed Shamekh; ashamekh{at}


The SARS-COV-2 pandemic led to the development of several vaccinations to contain the disease. The Pfizer-BioNTech COVID-19 (BNT162b2) vaccine was recommended on May 2021 for use in children above 12 years and older. The vaccine is safe, well tolerated and highly effective. Initial reports showed no serious adverse events; however, cases of myocarditis in young healthy male adolescents have been reported. We report two cases of myocarditis/perimyocarditis who presented with short history of chest pain following administration of the second dose of the MRN COVID-19 vaccine.

  • Cardiovascular system
  • Paediatrics (drugs and medicines)
  • Vaccination/immunisation
  • COVID-19

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Twitter @Colin Powell

  • Contributors This is to state that all authors contributed to this submission. AS: involved in the medical care of the patients, data collection and writing the manuscript. CP: revised the manuscript critically and approved it for publication. AA: participated in the writing of the manuscript. ISA: participated in the data collection and writing the manuscript. All Authors approved the version of the manuscript to be published.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.